Posted by Michael Wonder on 25 May 2022
Elevation Oncology announces FDA fast track designation granted to seribantumab for the tumour agnostic treatment of solid tumours harbouring NRG1 gene fusions
25 May 2022 - Elevation Oncology today announced that the U.S. FDA has granted fast track designation to seribantumab for the tumour agnostic treatment of advanced solid tumours that harbour NRG1 gene fusions.
Seribantumab is currently being evaluated in the ongoing Phase 2 CRESTONE study, for which initial data will be presented in an oral presentation at the upcoming American Society of Clinical Oncology 2022 Annual Meeting.
